Contact information
Juthathip Mongkolsapaya
Associate Professor
Our main research is to understand immune-responses, particularly antibody responses, against emerging pathogens, such as dengue virus, zika virus, HIV, Ebola virus, SARS and MERS and, the most recent, SARS-CoV2. We employ a wide range of approaches including virology, immunology, biochemistry, and structural biology to elucidate pathogenic mechanisms, to generate diagnostic and therapeutic reagents, design vaccines, and contributed to policy development. For example, during the COVID pandemic, we generated reagents that were involved in establishing a protocol to measure the antibody response, which have been used to monitoring the immune status in UK population. Hundreds of monoclonal antibodies were generated and characterised for their neutralisation activities, cross-reaction among the variants, and bio-physical properties. And in combination with crystal and cryo-EM structures, we described the antigenic distance among the variants and how new emerging variants escaped from existing immunity.
Recent publications
-
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.
Journal article
Dijokaite-Guraliuc A. et al, (2023), Cell reports, 42
-
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
Journal article
Huo J. et al, (2023), Cell Reports, 42, 111903 - 111903
-
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Journal article
Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13
-
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
-
Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins
Journal article
Renner M. et al, (2021), Nature Communications, 12